Reoperation for recurrent glioblastomas: What to expect?

Area of Science:

• Neuro-oncology
• Surgical oncology
• Clinical outcomes research

Background:

• Glioblastoma (GBM) treatment involves surgery, radiation, and chemotherapy, but recurrence is common.
• The efficacy of reoperation for recurrent GBM remains debated.
• This study investigates reoperation as a treatment strategy for GBM and its prognostic implications.

Purpose of the Study:

• To determine if reoperation is an effective treatment for glioblastoma (GBM).
• To identify circumstances under which GBM reoperation confers a better prognosis.
• To analyze factors influencing overall survival (OS) in GBM patients undergoing one or two surgeries.

Main Methods:

• Retrospective review of 286 newly diagnosed GBM cases (2008-2015).
• Multivariate Cox regression analysis to evaluate prognostic factors.
• Kaplan-Meier method for OS calculation and Weibull model for survival curve fitting.

Main Results:

• The reoperated group showed significantly longer overall survival (20.0 months vs. 11.4 months, P < 0.0001).
• Multivariate analysis linked survival to the number of surgeries, initial Karnofsky Performance Status, and age (P < 0.001).
• Weibull model estimated higher survival probabilities at 6, 12, and 24 months for reoperated patients.

Conclusions:

• Reoperation is a supported treatment indication for GBM, especially in younger patients with good functional status.
• Reoperation can potentially double survival rates at 12 and 24 months in selected GBM patients.
• This strategy offers improved prognosis under specific clinical conditions.